<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618913</url>
  </required_header>
  <id_info>
    <org_study_id>B0661150</org_study_id>
    <nct_id>NCT04618913</nct_id>
  </id_info>
  <brief_title>Anticoagulation in Patients With Venous Thromboembolism and Cancer</brief_title>
  <acronym>VICTORIE</acronym>
  <official_title>VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective analysis of observational cohorts using data from prospectively&#xD;
      collected administrative/claims data to investigate treatment patterns,healthcare resource&#xD;
      utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness&#xD;
      outcomes in patients with VTE and active cancer or patients with VTE and history of cancer&#xD;
      who initiate anticoagulant treatment with a VKA, LMWH or NOACs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of Thromboembolism</measure>
    <time_frame>6 Months after treatment began as early as 1/1/2013</time_frame>
    <description>The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first. As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Neoplasms</condition>
  <condition>Embolism</condition>
  <arm_group>
    <arm_group_label>VTE and history of cancer</arm_group_label>
    <description>VTE and history of cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <description>VTE and active cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Anticoagulant</description>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <arm_group_label>VTE and history of cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Anticoagulant</description>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <arm_group_label>VTE and history of cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Edoxaban</description>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <arm_group_label>VTE and history of cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran</description>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <arm_group_label>VTE and history of cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA</intervention_name>
    <description>Vitamin K antagonist</description>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <arm_group_label>VTE and history of cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMWH</intervention_name>
    <description>Low Molecular Weight Heparin</description>
    <arm_group_label>VTE and active cancer</arm_group_label>
    <arm_group_label>VTE and history of cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a diagnosis of (VTE) venous thromboembolism and active cancer, or a&#xD;
        history of cancer, being treated with anticoagulation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A VTE diagnosis&#xD;
&#xD;
          -  Active cancer or history of cancer&#xD;
&#xD;
          -  Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH&#xD;
&#xD;
          -  Age â‰¥ 18 years at the date of index VTE (Venous thromboembolic)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior VTE diagnosis&#xD;
&#xD;
          -  Diagnosis of prior atrial fibrillation&#xD;
&#xD;
          -  Inferior Vena Cava (IVC) filter&#xD;
&#xD;
          -  Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation -&#xD;
             note: Prophylactic use of (OAC)/(PAC) allowed.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed&#xD;
             on the index date.&#xD;
&#xD;
          -  Patients with less than one day of follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B0661150</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Eliquis</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Anti-Coagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

